Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Factors Affecting Drug Biotransformation: Biological

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The impact of piperazine and antipsychotic co-exposures and CB1 blockade on the effects elicited by AMB-FUBINACA, a synthetic cannabinoid, in mice.

European journal of pharmacology·2024

Same author

Utility of the second-generation curcumin analogue RL71 in canine histiocytic sarcoma.

Veterinary research communications·2023

Same author

The second-generation curcumin analogue RL71 elicits G2/M cell cycle arrest and apoptosis in canine osteosarcoma cells.

Veterinary and comparative oncology·2023

Same author

Investigating the Contribution of Major Drug-Metabolising Enzymes to Possum-Specific Fertility Control.

International journal of molecular sciences·2023

Same author

The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism.

Pharmacology, biochemistry, and behavior·2023

Same author

Characterisation of AMB-FUBINACA metabolism and CB<sub>1</sub>-mediated activity of its acid metabolite.

Forensic toxicology·2023

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Sex-specific differences in CYP450 isoforms in humans.

Marissa J Scandlyn¹, Emma C Stuart, Rhonda J Rosengren

¹University of Otago, Department of Pharmacology & Toxicology, Dunedin, New Zealand.

Expert Opinion on Drug Metabolism & Toxicology

|June 5, 2008

Summary

Sex differences in drug metabolism are significant. This review found higher CYP1A2 and CYP2E1 activity in males, but greater CYP3A activity in females, highlighting the need for more research on gender's role in drug efficacy.

More Related Videos

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Dissection of Larval Zebrafish Gonadal Tissue

Dissection of Larval Zebrafish Gonadal Tissue

Published on: April 26, 2017

Related Experiment Videos

Last Updated: Jul 4, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Dissection of Larval Zebrafish Gonadal Tissue

Dissection of Larval Zebrafish Gonadal Tissue

Published on: April 26, 2017

Area of Science:

Pharmacology and Toxicology
Drug Metabolism and Pharmacokinetics

Background:

Cytochrome P450 (CYP) enzyme activity is crucial for drug efficacy.
Understanding sex-dependent variations in CYP activity is vital for personalized medicine.

Purpose of the Study:

To review and summarize the sex-dependent activity of key CYP isoforms.
Specifically examined CYP3A, CYP1A2, CYP2D6, CYP2C9, CYP2C19, and CYP2E1.

Main Methods:

Conducted a literature search for human studies.
Hormonal status was not a restriction for study inclusion.

Main Results:

CYP2E1 and CYP1A2 activities appear higher in males compared to females.
CYP3A, a clinically significant isoform, shows greater activity in females.

Conclusions:

Current evidence suggests sex-based differences in the activity of specific CYP enzymes.
Further research is necessary to fully elucidate gender as a modulator of drug metabolism due to multifactorial influences.